ArticleBiology direct2026
The B7 family subgroup reflects tumor cell heterogeneity and patient post-operative prognosis in gallbladder cancer.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
Abstract
purposeTo elucidate the biological heterogeneity of gallbladder cancer (GBC) cells and refine post-operative risk stratification by investigating the expression and downstream signaling of the B7-family immune checkpoint molecules CD276 (B7-H3), VTCN1 (B7-H4), and HHLA2 (B7-H7) at single-cell resolution.
methodsSingle-cell RNA sequencing (scRNA-seq) data from seven primary tumors delineated five epithelial subgroups via non-negative matrix factorization (NMF). The functional association between HHLA2 and RAC1/CDC42-PAK1-Cofilin signaling was validated by lentiviral manipulation, pharmacologic inhibition, and subcutaneous xenografts. A total of 188 surgically treated GBC patients were enrolled for survival modeling. Seven machine-learning survival algorithms were trained on five variables (CD276, VTCN1, HHLA2 expression, tumor size, and differentiation) and compared by C-index, ROC-AUC, and calibration curves.
resultsCD276 + and VTCN1 + epithelial cells displayed pro-proliferative profiles, whereas HHLA2 + cells exhibited high EMT and migration signatures. HHLA2 overexpression led to increased RAC1/CDC42-PAK1-Cofilin signaling activity, enhanced proliferation, invasion, and EMT in vitro, and accelerated tumor growth in vivo. These effects were reversed by RAC1, CDC42, or PAK1 inhibitors, as well as by CFL1 knockdown. NMF classified tumor epithelial cells into five functionally distinct subgroups. A gradient-boosting machine (GBM) model integrating expression of the three B7 molecules with tumor size and differentiation achieved superior discrimination and accurate calibration on both the training and validation sets.
conclusionB7-family expression delineates biologically distinct GBC subpopulations; HHLA2 promotes EMT via RAC1/CDC42-PAK1-Cofilin signaling. The GBM model incorporating CD276, VTCN1, and HHLA2 expression with tumor size and differentiation demonstrates potential for enhanced post-operative risk stratification, offering promising candidates for biomarker development and targeted therapeutic interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.